367 related articles for article (PubMed ID: 17458562)
21. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
[TBL] [Abstract][Full Text] [Related]
22. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
[TBL] [Abstract][Full Text] [Related]
23. Workshop: options for therapy in ovarian cancer.
Herzog TJ; Holloway RW; Stuart GC
Gynecol Oncol; 2003 Sep; 90(3 Pt 2):S45-50. PubMed ID: 13129496
[TBL] [Abstract][Full Text] [Related]
24. Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma.
Gronlund B; Høgdall C; Hansen HH; Engelholm SA
Cancer; 2002 Apr; 94(7):1961-7. PubMed ID: 11932898
[TBL] [Abstract][Full Text] [Related]
25. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
Pujade-Lauraine E; Wagner U; Aavall-Lundqvist E; Gebski V; Heywood M; Vasey PA; Volgger B; Vergote I; Pignata S; Ferrero A; Sehouli J; Lortholary A; Kristensen G; Jackisch C; Joly F; Brown C; Le Fur N; du Bois A
J Clin Oncol; 2010 Jul; 28(20):3323-9. PubMed ID: 20498395
[TBL] [Abstract][Full Text] [Related]
26. Cost-minimization analysis of pegylated liposomal doxorubicin versus topotecan for the treatment of ovarian cancer in Italy.
Capri S; Cattaneo G
Clin Ther; 2003 Jun; 25(6):1826-45. PubMed ID: 12860501
[TBL] [Abstract][Full Text] [Related]
27. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
[TBL] [Abstract][Full Text] [Related]
28. A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK.
Smith DH; Adams JR; Johnston SR; Gordon A; Drummond MF; Bennett CL
Ann Oncol; 2002 Oct; 13(10):1590-7. PubMed ID: 12377647
[TBL] [Abstract][Full Text] [Related]
29. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
Mahner S; Meier W; du Bois A; Brown C; Lorusso D; Dell'Anna T; Cretin J; Havsteen H; Bessette P; Zeimet AG; Vergote I; Vasey P; Pujade-Lauraine E; Gladieff L; Ferrero A
Eur J Cancer; 2015 Feb; 51(3):352-8. PubMed ID: 25534295
[TBL] [Abstract][Full Text] [Related]
30. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
[TBL] [Abstract][Full Text] [Related]
31. Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.
Barnett JC; Alvarez Secord A; Cohn DE; Leath CA; Myers ER; Havrilesky LJ
Cancer; 2013 Oct; 119(20):3653-61. PubMed ID: 23921967
[TBL] [Abstract][Full Text] [Related]
32. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
Pignata S; Scambia G; Savarese A; Breda E; Sorio R; Pisano C; Lorusso D; Cognetti F; Vernaglia Lombardi A; Gebbia V; Scollo P; Morabito A; Signoriello G; Perrone F
Oncology; 2009; 76(1):49-54. PubMed ID: 19039248
[TBL] [Abstract][Full Text] [Related]
33. Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?
Gronlund B; Høgdall C; Christensen IJ; Engelholm SA; Hansen HH
Gynecol Oncol; 2004 Aug; 94(2):409-15. PubMed ID: 15297181
[TBL] [Abstract][Full Text] [Related]
34. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
[TBL] [Abstract][Full Text] [Related]
35. Randomized single-agents trials in recurrent epithelial ovarian cancer.
Sessa C; Marsoni S
Int J Gynecol Cancer; 2005; 15 Suppl 3():247-51. PubMed ID: 16343240
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial.
Seagle BL; Shahabi S
Gynecol Oncol; 2017 Apr; 145(1):9-14. PubMed ID: 28196674
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of chemotherapy according to
Brouillard-Saby F; Saint-Martin C; Ray-Coquard I; Gladieff L; Pomel C; Colombo PE; Classe JM; Chevrier M; Joly F; De la Motte Rouge T; Floquet A; Sabatier R; Barranger E; Costaz H; Leblanc E; Marchal F; Pautier P; Bosquet L; Rodrigues M
Int J Gynecol Cancer; 2023 Apr; 33(4):577-584. PubMed ID: 36631150
[TBL] [Abstract][Full Text] [Related]
38. Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer.
Havrilesky LJ; Garfield CF; Barnett JC; Cohn DE
Gynecol Oncol; 2012 Jun; 125(3):631-4. PubMed ID: 22446408
[TBL] [Abstract][Full Text] [Related]
39. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
Hoskins P; Vergote I; Cervantes A; Tu D; Stuart G; Zola P; Poveda A; Provencher D; Katsaros D; Ojeda B; Ghatage P; Grimshaw R; Casado A; Elit L; Mendiola C; Sugimoto A; D'Hondt V; Oza A; Germa JR; Roy M; Brotto L; Chen D; Eisenhauer EA
J Natl Cancer Inst; 2010 Oct; 102(20):1547-56. PubMed ID: 20937992
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
Gronlund B; Hansen HH; Høgdall C; Engelholm SA
Cancer; 2002 Oct; 95(8):1656-62. PubMed ID: 12365013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
